"Electrokinetic drug delivery has emerged as an alternative approach to overcome the limitations of, and to obviate the need for, hypodermic injection of many medications," said Pramodh Ishwarakrishnan, Frost & Sullivan Industry Analyst. "Transport Pharmaceuticals has achieved the noble distinction of creating a system which is poised to revolutionize the field of dermal drug delivery."
The Challenges and Promise of Transdermal Delivery
The outer layer of the skin, known as the stratum corneum, is a highly effective, impermeable barrier that serves as the immune system's natural first-line of defense. The stratum corneum prevents xenobiotics, external molecules or microorganisms from entering the body. It is this same barrier function that prevents topically applied drugs from reaching their target tissue in efficacious quantities.
The promise of Transport's technology lies in its ability to deliver a safe and effective therapeutic depot, directly in the affected tissue. The key advantages of this are two-fold; a high dose of potent drug rapidly and painlessly reaches the affected dermal tissue, while the patient avoids the potential toxicity and adverse effects associated with systemic exposure to a drug intended to act only on the skin. Transport's technology enhances both the delivery of topically applied drugs and the utility of potent, systemically delivered drugs, whose uses are limited by bioavailability, toxicity or side-effect concerns. While Transport's initial focus is herpes labialis, future indications include, onychomycosis, acne, actinic keratosis, keloids, warts, psoriasis, skin cancer and medical aesthetic applications.
About Best Practices
Frost & Sullivan Best Practices Awards recognize companies in a variety
of regional and g
|SOURCE Transport Pharmaceuticals|
Copyright©2007 PR Newswire.
All rights reserved